Hydroxyzine inhibits SARS-CoV-2 Spike protein binding to ACE2 in a qualitative in vitro assay
M. D. Rivas, J. M. R. Saponi-Cortes, J. Zamorano
This study shows hydroxyzine inhibits SARS-CoV-2 Spike protein binding to ACE2 in a qualitative in vitro assay, supporting its potential as a treatment for COVID-19.
bioRxiv · Jan 4, 2021 · PreprintImmunology